Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts

Colorectal cancer (CRC) shows variable response to immune checkpoint blockade, which can only partially be explained by high tumor mutational burden (TMB). We conducted an integrated study of the cancer tissue and associated tumor microenvironment (TME) from patients treated with pembrolizumab (KEYN...

Descripción completa

Detalles Bibliográficos
Autores: Bortolomeazzi, Michele, Keddar, Mohamed Reda, Montorsi, Lucía, Acha-Sagredo, Amelia, Benedetti, Lorena, Temelkovski, Damjan, Choi, Subin, Petrov, Nedyalko, Todd, Katrina, Wai, Patty, Kohl, Johannes, Denner, Tamara, Nye, Emma, Goldstone, Robert, Ward, Sophia, Wilson, Gareth A., Al Bakir, Maise, Swanton, Charles, John, Susan, Miles, James, Larijani, Banafshé, Kunene, Victoria, Fontana, Elisa, Arkenau, Hendrik-Tobias, Parker, Peter J., Rodríguez-Justo, Manuel, Shiu, Kai-Keen, Spencer, Jo, Ciccarelli, Francesca D.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/311282
Acceso en línea:http://hdl.handle.net/10261/311282
https://api.elsevier.com/content/abstract/scopus_id/85111546429
Access Level:acceso abierto
Palabra clave:Anti-PD1 Immunotherapy
CD8 T cells
Interferon Gamma
Tumor Mutational Burden
Wnt Signaling
Descripción
Sumario:Colorectal cancer (CRC) shows variable response to immune checkpoint blockade, which can only partially be explained by high tumor mutational burden (TMB). We conducted an integrated study of the cancer tissue and associated tumor microenvironment (TME) from patients treated with pembrolizumab (KEYNOTE 177 clinical trial) or nivolumab to dissect the cellular and molecular determinants of response to anti- programmed cell death 1 (PD1) immunotherapy.

Similares en LA Referencia